Despite heterogeneity in cancer risk by MMR gene mutation, current recommendations for LS gynecologic cancer prevention are not specific to genotype.3,4,9,10,11 Consequently, for patients with less aggressive phenotypes, such as individuals with PMS2 variants, current gene-agnostic management strategies may be associated with more harm than benefit. Here, PMS2 is linked to cancer.